Alaleh Nouri - 04 Dec 2024 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Role
EVP, CLO, CORP. SEC.
Signature
/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri
Issuer symbol
PRCT
Transactions as of
04 Dec 2024
Net transactions value
-$2,049,237
Form type
4
Filing time
06 Dec 2024, 16:17:52 UTC
Previous filing
18 Jun 2024
Next filing
05 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Options Exercise $86,062 +11,838 +23% $7.27 64,310 04 Dec 2024 Direct
transaction PRCT Common Stock Options Exercise $145,628 +4,162 +6.5% $34.99 68,472 04 Dec 2024 Direct
transaction PRCT Common Stock Options Exercise $447,646 +12,092 +18% $37.02 80,564 04 Dec 2024 Direct
transaction PRCT Common Stock Sale $364,006 -3,787 -4.7% $96.12 76,777 04 Dec 2024 Direct F1, F2
transaction PRCT Common Stock Sale $1,569,815 -16,187 -21% $96.98 60,590 04 Dec 2024 Direct F1, F3
transaction PRCT Common Stock Sale $794,752 -8,118 -13% $97.90 52,472 04 Dec 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -11,838 -36% $0.000000 21,056 04 Dec 2024 Common Stock 11,838 $7.27 Direct F5
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -4,162 -60% $0.000000 2,728 04 Dec 2024 Common Stock 4,162 $34.99 Direct F6
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -12,092 -32% $0.000000 26,094 04 Dec 2024 Common Stock 12,092 $37.02 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.55 to $96.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.56 to $97.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.58 to $98.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The Stock option was granted on June 22, 2021 and vested over a four year period.
F6 The Stock option was granted on March 31, 2022 and vested 1/48th on the anniversary of the vesting commencement date of March 15, 2022, and vesting monthly over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date.
F7 The Stock option was granted on March 5, 2023 and vests 1/48th of the shares monthly from the vesting commencement date of March 5, 2023 over a four year period thereafter, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date.